| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 3 Feb 2025 | 23 Jan 2025 |
| DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended December 31 2024 as per enclosed attachment. (As per BSE Announcement Dated on 03/02/2025) | ||
| Board Meeting | 9 Nov 2024 | 29 Oct 2024 |
| DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30 2024. Submission of financial results for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on 09.11.2024) | ||
| Board Meeting | 3 Aug 2024 | 25 Jul 2024 |
| DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30 2024. As per enclosed letter. Further to our intimation dated July 25, 2024, we would like to inform that the Board of Directors of the Company at its meeting held on August 03, 2024 has approved the unaudited financial results for the quarter ended June 30, 2024. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of standalone unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of consolidated unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 3. Press release on the financial results of the Company. Read less.. (As Per BSE Announcement Dated on 03.08.2024) | ||
| Board Meeting | 25 May 2024 | 15 May 2024 |
| DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Audited financial results for the quarter and year ended March 31 2024 and recommend dividend fi any on the equity shares of the Company for the financial year 2023-24. As per enclosed letter. (As Per BSE Announcement Dated on 25.05.2024) | ||
In a regulatory filing to the stock exchanges, Divi’s stated that the partnership is global in scope and is expected to significantly contribute to the company’s revenue over the coming years.
EBITDA reached ₹716 crore for the quarter, marking a 49.5% rise compared to ₹479 crore in Q2 2023.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
The company's first-quarter earnings before interest, taxes, depreciation, and amortisation (EBITDA) were ₹622 Crore.
Here are some of the stocks that may see significant price movement today: Ashoka Buildcon, JSW Steel, Ambuja Cements, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
